Appointments at Novavax, Halozyme and Abraxis – People on the move
Novavax has appointed John Trizzino to the newly created post of senior vice president (VP), international and governmental alliances.
In recent months Novavax has struck deals using its vaccine technology with governments around the globe and the creation of the position reflects this.
Trizzino has spent the past 12 years working in the vaccine and biotech markets at companies including MedImmune, ID Biomedical and Henry Schein.
Halozyme Therapeutics has appointed Jonathan Leff as VP and chief medical officer. Leff has previously worked at Roche, Amgen and Merck & Co.
Mary Lynne Hedley has been appointed as executive VP of operations and chief scientific officer at Abraxis BioScience. Most recently Hedley worked at Eisai and has also held positions at MGI Pharma and co-founded Zycos.
Algeta has appointed Gillies O’Bryan-Tear as chief medical officer. O’Bryan-Tear has more than 20 years experience in the pharma industry at companies including GlaxoSmithKline (GSK), Genzyme and Bristol-Myers Squibb.
He has been acting chief medical officer at Algeta since March and has worked as a consultant to the company since 2004.
The Medicines Company has appointed Scott Johnson as VP, new business ventures and chief medical officer. Johnson has been a director at the company since it formed in September 1996.
Benjamin Palleiko has been appointed as senior VP and chief financial officer at Ore Pharmaceuticals. Palleiko has experience in the pharma and banking sectors at companies including Penwest Pharmaceuticals.
Cellular Dynamics International has appointed Junying Yu as a senior research fellow. Yu has extensive academic research experience working with induced-pluripotent (iPS) stem cells.
